{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:33:20Z","timestamp":1773869600548,"version":"3.50.1"},"reference-count":17,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,11,9]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Sarcoidosis is a granulomatous disease that commonly presents with lung or lymphatic system manifestations. Diagnosis is often delayed due to variable clinical presentation. This is a case of a patient with metastatic clear cell ovarian cancer who developed disease reoccurence after definitive treatment with surgery and adjuvant chemotherapy. She was treated with multiple lines of therapy, including investigational agents. During this time, she developed mediastinal lymphadenopathy and hypercalcaemia. Due to suspicion that her presentation was not a manifestation of her malignancy, she underwent two lymph node biopsies revealing granulomatous disease. She was initiated on prednisone for management of sarcoidosis, which led to radiologic, laboratory and symptomatic improvement. Although the precipitating factor for this patient\u2019s sarcoidosis cannot be definitively determined, nivolumab is a possible culprit. This case highlights the importance of a broad differential diagnosis when a patient undergoing antineoplastic treatment develops mediastinal lymphadenopathy or hypercalcaemia.<\/jats:p>","DOI":"10.1136\/bcr-2021-247278","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T11:21:17Z","timestamp":1638876077000},"page":"e247278","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment-induced sarcoidosis in a patient with metastatic clear cell ovarian cancer"],"prefix":"10.1136","volume":"14","author":[{"given":"Kathryn","family":"DeCarli","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Lifespan Health System, Providence, Rhode Island, USA"},{"name":"Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Masel","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Lifespan Health System, Providence, Rhode Island, USA"},{"name":"Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Lifespan Health System, Providence, Rhode Island, USA"},{"name":"Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Lopresti","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Lifespan Health System, Providence, Rhode Island, USA"},{"name":"Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"2025082723324273000_14.12.e247278.1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"The Lancet"},{"key":"2025082723324273000_14.12.e247278.2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.mayocp.2016.03.004","article-title":"Pulmonary sarcoidosis: diagnosis and treatment","volume":"91","author":"Carmona","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2025082723324273000_14.12.e247278.3","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-210189"},{"key":"2025082723324273000_14.12.e247278.4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025082723324273000_14.12.e247278.5","article-title":"Cutaneous and pulmonary Sarcoid-Like reaction induced by nivolumab: case report and brief literature review","author":"Urrego-Callejas","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"2025082723324273000_14.12.e247278.6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-Like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025082723324273000_14.12.e247278.7","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025082723324273000_14.12.e247278.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201401-0188OC"},{"key":"2025082723324273000_14.12.e247278.9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0199-9"},{"key":"2025082723324273000_14.12.e247278.10","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.6198"},{"key":"2025082723324273000_14.12.e247278.11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudi\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025082723324273000_14.12.e247278.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.10.082"},{"key":"2025082723324273000_14.12.e247278.13","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000208259.73167.58"},{"key":"2025082723324273000_14.12.e247278.14","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.6032"},{"key":"2025082723324273000_14.12.e247278.15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133196","article-title":"Maximum tolerated dose and anti-tumor activity of intraperitoneal Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: phase I study results","volume":"13","author":"Coward","year":"2021","journal-title":"Cancers"},{"key":"2025082723324273000_14.12.e247278.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"2025082723324273000_14.12.e247278.17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med Overseas Ed"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-247278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:32:53Z","timestamp":1756362773000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-247278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,7]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bcr-2021-247278"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-247278","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}